All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the EHA 2022 Congress, the GvHD Hub was pleased to speak to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How do you optimize donor selection for allogeneic transplant? Comparing MSD, UD, and haploidentical donors.
How to optimize donor selection for allogeneic transplant?
Nagler begins by comparing leukemia-free and relapse-free survival with different donor types, including sibling, unrelated, mismatched, and haploidentical donors. Nagler goes on to talk about incidence of chronic GvHD (cGvHD) in transplant, and factors to consider when selecting a donor. Finally, Nagler discusses how to prevent GvHD and infections.
How do you select the optimal donor for transplant?
This interview with Arnon Nagler, Tel Aviv University, Tel Aviv, IL, was based on the question: How do you select the optimal donor for transplant?
Educational theme: Impact of the stem cell source on GvHD
Highlights of content that the GvHD Hub has previously published to enhance knowledge on the effect of stem cell source on GvHD risk and help clinicians make an informed decision when it comes...
Subscribe to get the best content related to GvHD delivered to your inbox